Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Rhabdoid Tumor 1Neuroectodermal Tumors, Primitive 1Meningeal Carcinomatosis 1Medulloblastoma 1Lung Neoplasms 1Infratentorial Neoplasms 1Ependymoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 15Temozolomide 11Vincristine 10Magnetic Resonance Spectroscopy 10Cisplatin 10Specimen Handling 8Radiotherapy 8Etoposide 8X-Rays 6Phantoms, Imaging 6Carboplatin 6Nuclear Medicine Department, Hospital 5Lomustine 5Radiation 4Platinum 4Methotrexate 4Irinotecan 4Filgrastim 4Biopsy 41,2-diaminocyclohexaneplatinum II citrate 4etoposide phosphate 3Thiotepa 3Nivolumab 3Granulocyte Colony-Stimulating Factor 3Celecoxib 3Bevacizumab 3Automobiles 3ulixertinib 2tipifarnib 2tazemetostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Medulloblastoma × Craniospinal Irradiation × 1 year × Clear all
NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
660 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡